Peregrine Announces Participation at Upcoming Investor Conferences
(firmenpresse) - TUSTIN, CA -- (Marketwire) -- 02/26/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will participate at the following investor conferences:
33rd Annual Cowen Health Care Conference
Tuesday, March 5, 2013, at 10:40am Eastern Standard Time
Marriott Copley Hotel Boston, Massachusetts
25th Annual ROTH Conference
Monday, March 18, 2013, at 2:00pm Pacific Daylight Time
The Ritz Carlton Hotel Dana Point, California
Stifel Nicolaus & Company Biotechnology Investor Day
Wednesday, March 20, 2013
San Francisco, California
Peregrine's presentations at the Cowen and Roth Conferences will be webcast live and available for replay until April 12, 2013 and April 25, 2013, respectively at: .
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at .
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.02.2013 - 21:00 Uhr
Sprache: Deutsch
News-ID 233626
Anzahl Zeichen: 0
contact information:
Town:
TUSTIN, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peregrine Announces Participation at Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Peregrine Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
